TNG908 for Solid Tumors

Recruiting at 20 trial locations

Overseen By Tango Clinical Trials

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Tango Therapeutics, Inc.

Must not be taking: Antiretrovirals

Disqualifiers: Active infection, Liver disease, Cardiovascular, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

192 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing TNG908, an oral drug, in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these specific cancer cells grow. The study will see if this treatment can help slow down or stop the cancer.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research Team

Maxim Pimkin, MD, PhD

Principal Investigator

Tango Therapeutics, Inc.

Eligibility Criteria

This trial is for adults (18+) with advanced or metastatic solid tumors that lack the MTAP protein, confirmed by specific tests. Participants must have tried standard treatments if available, be in fairly good health with a performance score of 0 to 1 or ≥70, and have functioning major organs. Pregnant women and those with significant medical conditions, allergies to TNG908, uncontrolled illnesses affecting study compliance, active infections requiring therapy, other cancers, certain heart diseases or HIV not meeting specific criteria are excluded.

Inclusion Criteria

I am 18 years old or older.

My tumor lacks the MTAP gene or protein.

I am fully active or able to carry out light work.

Exclusion Criteria

I am willing and able to follow the study's schedule and procedures.

I have another cancer besides the one being treated.

I am currently on medication for an infection.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

Participants with MTAP-deleted solid tumors receive escalating doses of TNG908 to estimate the MTD

16 weeks

Dose Expansion

Participants with specific MTAP-deleted tumor types receive TNG908 at the identified RP2D

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• TNG908

Trial Overview TNG908 is being tested on patients with MTAP-deleted solid tumors. It's an oral drug designed to inhibit PRMT5. The trial has two parts: dose escalation to find the safe amount people can take without too many side effects and dose expansion focusing on how well it works in particular tumor types.

Participant Groups

Group I: Dose Expansion in solid tumors Experimental Treatment 1 Intervention

Participants with other MTAP-deleted solid tumors will receive TNG908 at the identified RP2D

Group II: Dose Expansion in Sarcoma Experimental Treatment 1 Intervention

Participants with MTAP-deleted sarcoma (soft tissue and bone) will receive TNG908 at the identified RP2D

Group III: Dose Expansion in Pancreatic Ductal Adenocarcinoma Experimental Treatment 1 Intervention

Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG908 at the identified RP2D

Group IV: Dose Expansion in NSCLC Experimental Treatment 1 Intervention

Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D

Group V: Dose Expansion in Mesothelioma Experimental Treatment 1 Intervention

Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D

Group VI: Dose Expansion in Glioblastoma Experimental Treatment 1 Intervention

Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D

Group VII: Dose Escalation Experimental Treatment 1 Intervention

Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD

Who Is Running the Clinical Trial?

Tango Therapeutics, Inc.

Lead Sponsor

Trials

5

Recruited

740+